DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 hours ago

STE·STERIS plc

$.
-. (-.%)
High
$201.55
Open
$201.55
Market Cap
19.75B
52W High
$269.44
Low
$200.34
P. Close
$202.61
P/E
25.24
52W Low
$195.14
Fwd P/E
81.00
DailyIQ Est.
$260.95
Technical Score (1D)
23
SELL
News Sentiment
44
BEARISH
STE’s latest quarterly data, released just 1½ hours ago, shows annualized revenue growth at 7.5 %, noticeably below its five‑year trend, signaling a potential slowdown in demand for its medical‑device services. The company’s adjusted operating margin remains volatile, with no clear trajectory toward improvement, raising concerns that cost pressures may not be fully contained. Analysts have therefore issued a cautious stance, citing the lack of compelling catalysts and a modest entry price that limits upside potential. This combination of decelerating top‑line growth and margin uncertainty suggests that the stock may face downward pressure in the next 1–10 trading days as investors reassess its earnings outlook. Traders should weigh the risk of further margin tightening against the possibility that STE could implement cost‑control initiatives to stabilize profitability. The key to the next week will be how the company manages pricing power in a competitive market, as any failure to maintain or increase prices could erode margins further. Watch for any guidance on cost‑control measures or pricing strategy in the upcoming earnings call, which could shift sentiment. Additionally, keep an eye on early‑quarter sales data for the medical‑device sector, as a broader demand decline would reinforce the current concerns. Finally, monitor any regulatory or supply‑chain developments that could impact STE’s operational efficiency, as these could either mitigate or exacerbate the margin volatility noted in the latest report.
Earnings Summary
STERIS plc (STE) is a global provider of infection prevention solutions that serves the healthcare, pharmaceutical, and medical device industries through its Healthcare, Applied Sterilization Technologies, and Life Sciences segments. Operating in the medical devices sector, STERIS competes with other sterilization and consumable suppliers that support hospitals and manufacturing facilities. In the latest reporting period, the company reported Q4 2026 revenue of $1.5884 billion, a 7.3 percent decline from the consensus estimate of $1.6106 billion, and adjusted earnings per share of $2.83 versus an estimate of $2.84857, marking a miss in the most recent quarter; compared to Q3 2025, revenue rose from $1.4603 billion to $1.5884 billion, a 8.8 percent increase, while EPS grew from $2.47 to $2.83, a 14.5 percent jump, reflecting continued earnings strength despite the latest miss. Historically, STERIS has delivered revenue growth of roughly 7–8 percent year‑over‑year from 2024 to 2025 and has beaten consensus estimates in most quarters, with EPS beats in Q1 2025, Q2 2025, and Q3 2025, though the Q4 2026 miss signals potential cost‑control pressure; the company’s free‑cash‑flow margin of 16.4 percent remains solid, yet the lack of a forward guidance raises concerns about future capital deployment. Recent news indicates that STERIS’s Q4 2026 earnings fell short of consensus, prompting a reassessment of valuation and highlighting possible cost‑control challenges; meanwhile, a surge in options volume and a reported 9 percent revenue increase to $5.94 billion suggest bullish sentiment, while insider sales of 1,374 shares by CEO Daniel Carestio may reflect a planned liquidity event rather than a fundamental shift. Investors should watch for forthcoming guidance on revenue and margin targets, any updates on cost‑control initiatives or product pipeline progress, and broader healthcare equipment sector sentiment that could influence demand for STERIS’s infection‑control solutions.

EPS

EstBeatMiss
$2.18$2.37$2.56$2.75$2.94Q4'24Q1'25Q2'25Q3'25Q4'26Q3'26
QtrEstActual+/−
Q3'26$2.56 - -
Q4'26$2.85$2.83-0.7%
Q3'25$2.35$2.47+5.1%
Q2'25$2.26$2.34+3.4%
Q1'25$2.60$2.74+5.4%
Q4'24$2.32$2.32-0.1%

Revenue

EstBeatMiss
$1.3B$1.4B$1.5B$1.6B$1.6BQ4'24Q1'25Q2'25Q3'25Q4'26Q3'26
QtrEstActual+/−
Q3'26$1.5B - -
Q4'26$1.6B$1.6B-1.4%
Q3'25 - $1.5B -
Q2'25 - $1.4B -
Q1'25 - $1.5B -
Q4'24 - $1.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

STE Stock Snapshot

STE is currently trading at $200.81, giving STERIS plc a market cap of 19.75B and a P/E ratio of 25.2. Today's range spans $200.34–$201.55, with shares opening at $201.55 and moving down $1.80 (0.9%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 44/100.

Over the past year STE has traded between $195.14 and $269.44 - the current price is +2.9% off the 52-week low and -25.5% from the high. 17 analysts cover the stock with a Buy consensus and a mean 12-month target of $256.86 (range $225.00–$280.00), implying upside of +27.9%.

The options market is expressing concern about STE - elevated put activity in large-cap Healthcare names with SELL signals (23/100) is common when the technical and sentiment inputs (neutral, 44/100) both deteriorate. Price: $200.81 (near 52-week lows). (P/E: 25.2) At 19.75B in capitalization, that hedging activity from institutional holders can become a feedback loop that amplifies the initial selling pressure. Range: $195.14–$269.44.

When a large-cap Healthcare name with 19.75B in capitalization prints a SELL signal (23/100) alongside neutral news sentiment (44/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $200.81 (near 52-week lows in the $195.14–$269.44 range), the structural support levels are where that sponsorship question gets answered.